167 related articles for article (PubMed ID: 19562501)
1. IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: a case report.
Martinez-Redondo C; Ortuño FJ; Lozano ML; Jerez A; del Mar Osma M; Giraldo P; Vicente V
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S265-7. PubMed ID: 19562501
[TBL] [Abstract][Full Text] [Related]
2. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.
Camou F; Viallard JF
Blood Cells Mol Dis; 2012 Jan; 48(1):51-2. PubMed ID: 21983348
[No Abstract] [Full Text] [Related]
3. Immunoglobulin abnormalities and effects of enzyme replacement therapy in children with Gaucher disease.
Arıkan-Ayyıldız Z; Yuce A; Uslu-Kızılkan N; Demir H; Gurakan F
Pediatr Blood Cancer; 2011 Apr; 56(4):664-6. PubMed ID: 21298757
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy leading to improvement in myeloma indices in a patient with concomitant Gaucher disease.
Harel R; Gavish I; Aviv A; Greenman Maravi N; Trougouboff P; Zimran A; Revel-Vilk S
Intern Med J; 2022 May; 52(5):872-875. PubMed ID: 35538014
[TBL] [Abstract][Full Text] [Related]
5. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
[TBL] [Abstract][Full Text] [Related]
6. Cholangiocarcinoma occurring in a patient with type 1 Gaucher disease treated with velaglucerase alfa enzyme replacement therapy: First case report.
Holubar J; Bres V; Costes-Martineau V; Pers YM
Blood Cells Mol Dis; 2018 Feb; 68():112-114. PubMed ID: 28559130
[No Abstract] [Full Text] [Related]
7. Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher's disease.
Deibener J; Kaminsky P; Jacob C; Dousset B; Klein M; Duc M
Haematologica; 1998 May; 83(5):479-80. PubMed ID: 9658738
[TBL] [Abstract][Full Text] [Related]
8. Effect of treatment on biclonal gammopathy associated with Gaucher disease.
Decaux O; Ruelland A; Grosbois B
J Inherit Metab Dis; 2007 Oct; 30(5):824. PubMed ID: 17879146
[TBL] [Abstract][Full Text] [Related]
9. Effect of enzyme replacement therapy on gammopathies in Gaucher disease.
Brautbar A; Elstein D; Pines G; Abrahamov A; Zimran A
Blood Cells Mol Dis; 2004; 32(1):214-7. PubMed ID: 14757437
[TBL] [Abstract][Full Text] [Related]
10. A synchronous therapy with daratumumab and enzymatic replacement therapy (ERT) in a patient with Gaucher disease and multiple myeloma.
Rago A; Palumbo G; Tordi A; Bianchi S; Offidani M; di Toritto TC
Ann Hematol; 2023 Oct; 102(10):2977-2978. PubMed ID: 37432414
[No Abstract] [Full Text] [Related]
11. Hyperimmunoglobulinemia in pediatric-onset type 1 Gaucher disease and effects of enzyme replacement therapy.
Wine E; Yaniv I; Cohen IJ
J Pediatr Hematol Oncol; 2007 Jul; 29(7):451-7. PubMed ID: 17609622
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary arterial hypertension with plexogenic arteriopathy in enzyme-substituted Gaucher disease.
den Bakker MA; Grünberg K; Boonstra A; van Hal PT; Hollak CE
Histopathology; 2012 Aug; 61(2):324-6. PubMed ID: 22690977
[No Abstract] [Full Text] [Related]
13. Enzyme Replacement Therapy in a Gaucher Family.
Erdem N; Buran T; Berber I; Aydogdu I
J Natl Med Assoc; 2018 Aug; 110(4):330-333. PubMed ID: 30126557
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy for mild patients with Gaucher disease.
Zimran A; Ilan Y; Elstein D
Am J Hematol; 2009 Apr; 84(4):202-4. PubMed ID: 19229987
[No Abstract] [Full Text] [Related]
15. Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy--unsuccessful treatment of the neurological abnormality in type 2 Gaucher disease.
Migita M; Hamada H; Fujimura J; Watanabe A; Shimada T; Fukunaga Y
Eur J Pediatr; 2003 Jul; 162(7-8):524-525. PubMed ID: 12845529
[No Abstract] [Full Text] [Related]
16. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
[No Abstract] [Full Text] [Related]
17. Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States.
Abell K; Chadwell SE; Burrow TA; Becker APP; Bailey L; Steele P; Zhang X; Islas-Ohlmayer M; Bittencourt R; Schwartz IVD; Prada CE
Am J Med Genet C Semin Med Genet; 2020 Dec; 184(4):1052-1059. PubMed ID: 33277783
[TBL] [Abstract][Full Text] [Related]
18. Neuropathy associated with monoclonal gammopathies of undetermined significance.
Gosselin S; Kyle RA; Dyck PJ
Ann Neurol; 1991 Jul; 30(1):54-61. PubMed ID: 1656848
[TBL] [Abstract][Full Text] [Related]
19. Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy.
Elstein D; Abrahamov A; Altarescu G; Zimran A
Blood Cells Mol Dis; 2013 Feb; 50(2):140. PubMed ID: 23085428
[No Abstract] [Full Text] [Related]
20. Retinal Deposits in a Young Woman.
Oliver R; Sallam AB; Uwaydat SH
JAMA Ophthalmol; 2018 Jun; 136(6):708-709. PubMed ID: 29522126
[No Abstract] [Full Text] [Related]
[Next] [New Search]
